Clinical Investigation

Kidney International (1991) 39, 1255–1266; doi:10.1038/ki.1991.159

Additive and synergistic effects of cyclosporine metabolites on glomerular mesangial cells

Heinfried H Radeke1, Uwe Christians1, Jörg S Bleck1, Karl-F Sewing1 and Klaus Resch1

1Abteilung Molekularpharmakologie, Abteilung Allgemeine Pharmakologie, and Abteilung Gastroenterologie, Medizinische Hochschule, Hannover, Germany

Correspondence: Dr med Heinfried H Radeke, Abt. Molekular-pharmakologie, Medizinische Hochschule, Konstanty-Gutschow-Str. 8, D-3000 Hannover 61, Germany.

Received 3 May 1990; Revised 21 January 1991; Accepted 23 January 1991.

Top

Abstract

Additive and synergistic effects of cyclosporine metabolites on glomerular mesangial cells. Out of the 29 cyclosporin (Cs) metabolites defined so far, 10 representative ones were isolated from bile of liver grafted patients, purified by HPLC, and their structure specified by FAB-MS and 1H NMR. These were used to determine the growth inhibitory effects on Sprague Dawley rat glomerular mesangial cells (MC). Metabolite dilutions were added to cultured MC for 72 hours and [3H]-thymidine incorporation was measured. A 50% growth inhibition by single metabolites (M) on MC was achieved at the following concentrations (mg/liter): Cs: 1.25; M21: 6.0; M18: 9.0; M26: 10.5; M1: 10.8; M8: 10.8; M17: 12.5; M13: >20.0;M25: >25.0; M203-218: >50.0;H355: >50.0. The activity was correlated to the degree of metabolization as the group of six "active" compounds included four primary metabolites (hydroxylated or demethylated derivatives of Cs: M21, M18, Ml, M17), whereas the four "inactive" compounds exclusively were secondary metabolites (demethylated, hydroxylated and/or oxidized primary metabolites: M13, M25, M203-218, H355). Combinations of active metabolites with or without Cs resulted in an additive antiproliferative effect. Although single metabolite activities are not relevant in vivo, already combinations of three (M1 + M17 + M18) or four metabolites (M17 + M18 + M21 + H355) resulted in a significant growth inhibition at concentrations of the participating metabolites measured in urine of liver transplanted patients. Moreover, significant synergistic activities were determined with combinations including secondary metabolites. A final set of experiments discharged unspecific cytotoxic effects. The inhibition of MC [3H]-thymidine incorporation was completely reversible and moreover, direct mesangiolysis was excluded for both single and combined metabolite actions. Thus, considering rat MC proliferation as an initial kidney cell model system for subsequent, more detailed studies measuring functional parameters, we have demonstrated that activities of single metabolites are related to their chemical structure. More importantly, mimicking to some extent the patients' situation, combinations of metabolites at concentrations occurring in vivo reduced MC proliferation in culture in an at least an additive fashion, suggesting that side effects of Cs treatment might be attributed to combined Cs metabolite actions.

Top

References

  1. Kahan BD: Cyclosporine. N Engl J Med 321(25):1725–1738, 1989 | PubMed | ISI | ChemPort |
  2. Berg KJ, Foerre O, Bjerkhoel F, Amundsen E, Djoeseland O, Rugstad HE, Westre B: Side effects of cyclosporin A treatment in patients with rheumatoid arthritis. Kidney Int 29:1180–1187, 1986 | PubMed | ISI | ChemPort |
  3. Mihatsch MJ, Bach JF, Coovadia HM, Foerre O, Moutsopoulos HM, Drosos AA, Siamopoulos KC, Noël LH, Ramsaroop R, Hàllgren R, Svenson K, Bohmann SO: Cyclosporin-associated nephropathy in patients with autoimmune diseases. Klin Wochenschr 66:43–47, 1988
  4. Lucey MR, Kolars JC, Merion RM, Campbell DA, Aldrich M, Watkins PB: Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet 335:11–15, 1990 | Article | PubMed | ChemPort |
  5. Myers BD, Sibley R, Newton L, Tomlanovich SJ, Boshkos C, Stinson E, Luetscher JA, Whitney DJ, Krasny D, Coplon NS, Perlroth MG: The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int 33:590–600, 1988 | PubMed | ISI | ChemPort |
  6. Kunzendorf U, Brockmöller J, Jochimsen F, Roots I, Offermann G: Neurotoxicity caused by a high cyclosporine metabolite level. Transplantation 48:531–532, 1989
  7. Kohlhaw K, Wonigeit K, Schäfer O, Ringe B, Bunzendahl H, Pichlmayr R: Association of very high blood levels of cyclosporin metabolites with clinical complications after liver transplantation. Transplant Proc 21:2232–2233, 1989 | PubMed | ChemPort |
  8. Humes HD, Jackson NM, O'Connor RP, Hunt DA, White MD: Pathogenic mechanisms of nephrotoxicity: Insights into cyclosporine nephrotoxicity. Transplant Proc 17(Suppl 1):51–62, 1985
  9. Ryffel B: Pharmacology of cyclosporine. VI. Cellular activation: Regulation of intracellular events by cyclosporine. Pharmacol Rev 41:407–422, 1989
  10. Pavoa Dos Santos OF, Boim M, Bregman R, Draibe SA, Barros EJG, Pirotzky E, Schor N, Braquet P: Effect of platelet-activating factor antagonist on cyclosporine nephrotoxicity. Transplantation 47:592–595, 1989
  11. Murray BM, Paller MS, Ferris TF: Effect of cyclosporine administration on renal hemodynamics in concious rats. Kidney Int 28:767–774, 1985 | PubMed | ISI | ChemPort |
  12. Scherrer U, Vissing SF, Morgan BJ, Rollins JA, Tindall RSA, Ring S, Hanson P, Mohanty PK, Victor RG: Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 323:693–699, 1990 | PubMed | ISI | ChemPort |
  13. Perico N, Benigni A, Bosco E, Rossini M, Orisio S, Ghilardi F, Piccinelli A, Remuzzi G: Acute cyclosporine A nephrotoxicity in rats: which role for renin-angiotensin system and glomerular prostaglandins? Clin Nephrol 25(Suppl 1):83–88, 1986
  14. Makowka L, Lopatin W, Gilas T, Falk J, Phillips MJ, Falk R: Prevention of cyclosporine (CyA) nephrotoxicity by synthetic prostaglandins. Clin Nephrol 25(Suppl 1):89–94, 1986
  15. Ryffel B, Donatsch P, Hiestand P, Mihatsch MJ: PGE2 reduces nephrotoxicity and immunosuppression of cyclosporine in rats. Clin Nephrol 25(Suppl 1):95–99, 1986
  16. Rodríguez-Puyol D, Lamas S, Olivera A, López-Farré A, Ortega G, Hernando L, López-Novoa JM: Actions of cyclosporin A on cultured rat mesangial cells. Kidney Int 35:632–637, 1989 | PubMed | ChemPort |
  17. Stahl RAK, Kudelka S: Chronic cyclosporine A treatment reduces prostaglandin E2 formation in isolated glomeruli and papilla of rat kidneys. Clin Nephrol 25(Suppl 1):78–82, 1986
  18. Moran M, Mozes MF, Maddux MS: Prevention of acute graft rejection by the prostaglandin E1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. N Engl J Med 322:1183–1188, 1990
  19. Quarto Di Palo F, Elli A, Palazzi P, Parenti M, Rivolta R, Zanussi C: Role of a prostaglandin E1 analogue in the prevention of acute graft rejection by cyclosporine. N Engl J Med 323:832–833, 1990
  20. Goldberg HJ, Wong PY, Cole EH, Levy GA, Skorecki KL: Dissociation between the immunosuppressive activity of cyclosporine derivatives and their effects on intracellular calcium signaling in mesangial cells. Transplantation 47:731–732, 1989 | PubMed | ChemPort |
  21. Pfeilschifter J: Cyclosporin A augments vasoconstrictor-induced rise in intracellular free calcium in rat renal mesangial cells. J Biochem Pharmacol 37:4205–4210, 1988
  22. Meyer-Lehnert H, Schrier RW: Cyclosporin A enhanced vasopressin-induced Ca2+ mobilization and contraction of mesangial cells. Kidney Int 34:89–97, 1988
  23. Meyer-Lehnert H, Schrier RW: Potential mechanism of cyclosporin A-induced vascular smooth muscle contraction. Hypertension 13:352–360, 1989 | PubMed | ChemPort |
  24. Martin M, Krichbaum M, Kaever V, Goppelt-Strübe M, Resch K: Cyclosporin A suppresses proliferation of renal mesangial cells in culture. Biochem Pharmacol 37:1083–1088, 1988
  25. Kumano K, Yoshida K, Iwamura M, Endo T, Sakai T, Nakamura K, Kuwao T: The role of reactive oxygen species in cyclosporin A induced nephrotoxicity in rats. Transplant Proc 21:941–942, 1989
  26. Radeke HH, Meier B, Topley N, Flöge J, Habermehl GG, Resch K: Interleukin 1-alpha and tumor necrosis factor-alpha induce oxygen radical production in mesangial cells. Kidney Int 37:767–775, 1990 | Article | PubMed | ISI | ChemPort |
  27. Cole E, Cheung F, Wong PY, Fung LS, Skorecki K, Levy GA: Toxic effects on renal cells in culture—A comparison of cyclosporin A and its metabolites. Transplant Proc 21:943–945, 1989
  28. Wallemacq PE, Lhoëst G, Latinne D, De Bruyère M: Isolation, characterization and in vitro activity of human cyclosporin A metabolites. Transplant Proc 21(1):906–910, 1989
  29. Fahr A, Hiestand P, Ryffel B: Studies on the biologic activities of Sandimmun metabolites in humans and in animal models: Review and original experiments. Transplant Proc 22:1116–1124, 1990
  30. Zeevi A, Eiras G, Burckart G, Makowka L, Venkataramanan R, Wang CP, Van Thiel DH, Murase N, Starzl TE, Duquesnoy R: Immunosuppressive effect of cyclosporine metabolites from human bile on autoreactive T cells. Transplant Proc 20(Suppl 2):115–121, 1988
  31. Sewing K-F, Christians U, Kohlhaw K, Radeke HH, Strohmeyer S, Kownatzki R, Budnial J, Schottmann R, Bleck JS, Almeida VMF, Deters M, Wonigeit K, Pichlmayr R: Biological activity of ciclosporin metabolites. Transplant Proc 22(3):1129–1134, 1990
  32. Christians U, Schlitt HJ, Bleck JS, Schiebel HM, Kownatzki R, Maurer G, Strohmeyer SS, Schottmann R, Wonigeit K, Pichlmayr R, Sewing K-F: Measurement of cyclosporine and 18 metabolites in blood, bile, and urine by high-performance liquid chromatography. Transplant Proc 20(2):608–613, 1988
  33. Kahau BD, Shaw LM, Holt D, Grevel J, Johnston A: Consensus Document, Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Transplant Proc 22(3):1357–1361, 1990
  34. Maurer G, Loosli R, Schreier E, Keller H: Disposition of cyclosporine in several animal species and man—Structural elucidation of its metabolites. Drug Metab Dispos 12:120–126, 1984 | PubMed | ChemPort |
  35. Ryffel B, Hiestand P, Foxwell B, Donatsch P, Boelsterli HJ, Maurer G, Mihatsch MJ: Nephrotoxic and immunosuppressive potentials of cyclosporine metabolites in rats. Transplant Proc 18(Suppl 5):41–45, 1986
  36. Rosano TG, Freed BM, Pell MA, Lempert N: Cyclosporine metabolites in human blood and renal tissue. Transplant Proc 18(Suppl 5):35–40, 1986
  37. Ryffel B: Toxicology—Experimental studies. Prog Allergy 38:181–197, 1986
  38. Emmel EA, Verweij CL, Durand DB, Higgins KM, Lacy E, Crabtree GR: Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science 246:1617–1620, 1989 | Article | PubMed | ISI | ChemPort |

Extra navigation

.
ADVERTISEMENT